Mobotinib/Mobotinib Side Effects

Mobocertinib/Mobocertinib is a new type of targeted therapy drug mainly used to treat specific types of non-small cell lung cancer (NSCLC). Although the drug has shown good efficacy in clinical applications, various side effects may occur during use. These side effects need to be fully understood by doctors and patients in order to respond and manage them in a timely manner.

In clinical studies of moboxetinib, the most common side effects include adverse reactions with an incidence rate exceeding 20%, mainly diarrhea, rash, nausea, stomatitis, vomiting, decreased appetite, paronychia, fatigue, dry skin and musculoskeletal pain.

In terms of laboratory tests,Grade 3 or 4 laboratory abnormalities occurring in ≥2% of patients included lymphopenia, increased amylase, increased lipase, decreased potassium, decreased hemoglobin, increased creatinine, and decreased magnesium. These laboratory abnormalities reflect the drug's potential effects on body metabolism and organ function. For example, lymphopenia may affect a patient's immunity, making them more susceptible to infections, while electrolyte imbalances such as decreased potassium and magnesium may cause serious complications such as cardiac arrhythmia.

It is worth noting that ≥2% of patients may experience serious adverse reactions, including diarrhea, dyspnea, vomiting, fever, acute kidney injury, nausea, pleural effusion, and heart failure. These serious adverse reactions often require immediate medical intervention to prevent further worsening of the condition. During the period of treatment with mobosetinib, patients should undergo regular follow-up examinations, monitor possible side effects, and communicate with medical staff in a timely manner to ensure that any uncomfortable symptoms can be responded to quickly.